GLP-1 Receptor Agonists Reduce Cardiac Dysfunction in Cancer
Over a 12-month follow-up period, GLP-1 receptor agonists were associated with a significantly reduced risk of CTRCD, as well as lower rates of all-cause mortality, hospital admission, atherosclerotic events, and thrombotic complications.